Base de dados : MEDLINE
Pesquisa : D04.210.500.745.432.531.500 [Categoria DeCS]
Referências encontradas : 838 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 84 ir para página                         

  1 / 838 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28526167
[Au] Autor:Park JY; Seong SJ; Kim TJ; Kim JW; Bae DS; Nam JH
[Ad] Endereço:Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
[Ti] Título:Significance of body weight change during fertility-sparing progestin therapy in young women with early endometrial cancer.
[So] Source:Gynecol Oncol;146(1):39-43, 2017 Jul.
[Is] ISSN:1095-6859
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate the influence of body weight change during fertility-sparing progestin therapy on oncologic and reproductive outcomes in young women with early-stage endometrial cancer who did not complete child bearing. METHODS: This multicenter, retrospective study included 154 young patients with well-differentiated, endometrium-confined endometrioid endometrial adenocarcinoma on magnetic resonance imaging who received fertility-sparing progestin therapy. RESULTS: The mean body weight and body mass index (BMI) at baseline and progestin therapy completion was 65.3±16.2 and 66.5±15.9kg (P=0.044), respectively, and 25.51±5.99 and 25.99±5.94kg/m (P=0.034), respectively. During progestin therapy, 51 (33.1%), 29 (18.8%), and 74 patients (48.1%) had weight loss, no weight change, and weight gain, respectively, of which 11 (7.1%) had 10% weight loss and 30 (19.5%) had 10% weight gain. A pretreatment BMI of ≥25kg/m was significantly associated with a lower complete response rate to progestin therapy (P=0.003) and a high recurrence rate (P=0.033). A posttreatment BMI of ≥25kg/m was also a significant factor for high recurrence rate (P=0.049). However, weight change during therapy was not significantly associated with complete response or recurrence rate. Pre and posttreatment BMIs and weight change were not associated with pregnancy and live birth rates. CONCLUSION: Weight change during progestin therapy has little influence on complete response, recurrence, pregnancy, and live birth rates. However, pre and posttreatment BMIs of ≥25kg/m were significant predictors for poor treatment response and high recurrence. Therefore, it is important to maintain patients' normal BMIs during progestin therapy.
[Mh] Termos MeSH primário: Antineoplásicos Hormonais/administração & dosagem
Peso Corporal/efeitos dos fármacos
Neoplasias do Endométrio/tratamento farmacológico
Neoplasias do Endométrio/fisiopatologia
Preservação da Fertilidade/métodos
Progestinas/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Índice de Massa Corporal
Neoplasias do Endométrio/patologia
Feminino
Seres Humanos
Acetato de Medroxiprogesterona/administração & dosagem
Acetato de Megestrol/administração & dosagem
Estadiamento de Neoplasias
Gravidez
Resultado da Gravidez
Taxa de Gravidez
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Antineoplastic Agents, Hormonal); 0 (Progestins); C2QI4IOI2G (Medroxyprogesterone Acetate); TJ2M0FR8ES (Megestrol Acetate)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170713
[Lr] Data última revisão:
170713
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170521
[St] Status:MEDLINE


  2 / 838 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28353144
[Au] Autor:Moradan S; Nikkhah N; Mirmohammadkhanai M
[Ad] Endereço:Gynecologist, Abnormal Uterine Bleeding Research Center, Semnan University of Medical Sciences, Semnan, Iran.
[Ti] Título:Comparing the Administration of Letrozole and Megestrol Acetate in the Treatment of Women with Simple Endometrial Hyperplasia without Atypia: A Randomized Clinical Trial.
[So] Source:Adv Ther;34(5):1211-1220, 2017 May.
[Is] ISSN:1865-8652
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The present study was conducted as a pilot to compare the therapeutic effects and the potential side effects of oral Megestrol acetate and Letrozole in the treatment of simple hyperplasia in perimenopausal women. METHODS: The participants of this randomized clinical trial consisted of two groups of 25 women aged 44-50 presenting with abnormal uterine bleeding diagnosed with simple endometrial hyperplasia without cytologic atypia confirmed by transvaginal ultrasonography and biopsy. The first group received 40-mg doses of Megestrol acetate for 2 weeks per month for a total period of 2 months. The second group received 2.5-mg daily doses of Letrozole for a total period of 2 months. The differences in terms of quantitative measurements were analyzed using the independent two-sample t test and the paired t test. To compare the two groups in terms of the distribution of the categorical variables, Pearson's Chi square and Fisher's Exact tests were used at the significance level of 0.05 by Stata-9.2. RESULTS: Although the intervention led to significant improvements in both groups (P < .001), there was no difference between the groups in terms of accomplishing resolution (P = .74) [seven (28%) patients in the Letrozole group and five (20%) in the Megestrol group], while two patients in the Letrozole group and nine in the Megestrol group suffered from side effects, suggesting significantly lower side effects in the Letrozole group (P = .02). CONCLUSION: Letrozole and Megestrol acetate seem to have similar effects on the treatment of simple endometrial hyperplasia, the only difference being that Letrozole presents fewer side effects than Megestrol acetate in patients with this condition. FUNDING: Abnormal Uterine Bleeding Research Center of Semnan University of Medical Sciences, Semnan, Iran. TRIAL REGISTRATION: IRCT2015031011504N5.
[Mh] Termos MeSH primário: Hiperplasia Endometrial/tratamento farmacológico
Acetato de Megestrol/uso terapêutico
Nitrilos/uso terapêutico
Triazóis/uso terapêutico
[Mh] Termos MeSH secundário: Administração Oral
Adulto
Feminino
Seres Humanos
Meia-Idade
Projetos Piloto
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Nitriles); 0 (Triazoles); 7LKK855W8I (letrozole); TJ2M0FR8ES (Megestrol Acetate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:T
[Da] Data de entrada para processamento:170330
[St] Status:MEDLINE
[do] DOI:10.1007/s12325-017-0509-8


  3 / 838 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28026855
[Au] Autor:Greenwald ZR; Huang LN; Wissing MD; Franco EL; Gotlieb WH
[Ad] Endereço:Division of Cancer Epidemiology, McGill University, Montreal, Quebec, Canada.
[Ti] Título:Does hormonal therapy for fertility preservation affect the survival of young women with early-stage endometrial cancer?
[So] Source:Cancer;123(9):1545-1554, 2017 May 01.
[Is] ISSN:1097-0142
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The incidence of endometrial cancer among young women is increasing. Some patients with low-grade endometrial cancer receive hormone therapy (HT) before surgery to preserve fertility. It is unclear whether this adversely affects survival. METHODS: Patients with localized, low-grade endometrial cancer who were aged <45 years were selected from the Surveillance, Epidemiology, and End Results database between 1993 and 2012. Propensity score matching was used to select comparable groups receiving HT or primary surgery. Cancer-specific and overall survival were measured using Kaplan-Meier methods. Hazard ratios and 95% confidence intervals (95% CIs) were estimated using Cox models adjusted for age, period of diagnosis, marital status, race, tumor grade, morphology, and previous radiotherapy. RESULTS: A total of 6339 women were included in the current study cohort, 161 of whom initially received HT and 6178 of whom received primary surgery. After 15 years of follow-up, all-cause mortality did not differ between the groups (HT group: 14.1% [95% CI, 6.7%-28.4%] and propensity score-matched primary surgery group: 9.3% [95% CI, 4.1%-20.5%]). Cancer-specific mortality appeared higher in patients treated with HT compared with those treated with primary surgery (9.2% [95% CI, 3.4%-24.0%] vs 2.1% [95% CI, 1.5%-2.8%]). However, this difference was driven by 3 late deaths in the HT group. Sensitivity analyses using a broader definition of cancer-specific mortality provided no statistical evidence of a survival difference between the treatment groups. The hazard ratio for the overall risk of death was 1.45 (95% CI, 0.44-4.74). CONCLUSIONS: Based on this population-based cohort, young patients with low-grade endometrial cancer appear to have excellent survival, regardless of the primary therapy chosen (HT vs primary surgery). The current selection of patients for HT to preserve fertility, which is managed carefully by experienced clinicians, does not appear to significantly worsen clinical outcomes. Cancer 2017;123:1545-1554. © 2017 American Cancer Society.
[Mh] Termos MeSH primário: Antineoplásicos Hormonais/uso terapêutico
Carcinoma Endometrioide/tratamento farmacológico
Neoplasias do Endométrio/tratamento farmacológico
Preservação da Fertilidade/métodos
Histerectomia
[Mh] Termos MeSH secundário: Adulto
Carcinoma Endometrioide/mortalidade
Causas de Morte
Estudos de Coortes
Neoplasias do Endométrio/mortalidade
Feminino
Seres Humanos
Estimativa de Kaplan-Meier
Medroxiprogesterona/uso terapêutico
Acetato de Medroxiprogesterona/uso terapêutico
Acetato de Megestrol/uso terapêutico
Gradação de Tumores
Pontuação de Propensão
Modelos de Riscos Proporcionais
Programa de SEER
Fatores de Tempo
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Antineoplastic Agents, Hormonal); C2QI4IOI2G (Medroxyprogesterone Acetate); HSU1C9YRES (Medroxyprogesterone); TJ2M0FR8ES (Megestrol Acetate)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170811
[Lr] Data última revisão:
170811
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161228
[St] Status:MEDLINE
[do] DOI:10.1002/cncr.30529


  4 / 838 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27670256
[Au] Autor:Falcone F; Laurelli G; Losito S; Di Napoli M; Granata V; Greggi S
[Ad] Endereço:Gynecologic Oncology Surgery, National Cancer Institute of Naples-IRCCS "Fondazione G. Pascale", Naples, Italy.
[Ti] Título:Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer.
[So] Source:J Gynecol Oncol;28(1):e2, 2017 Jan.
[Is] ISSN:2005-0399
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To report our 15-year institutional experience of fertility-sparing treatment in young patients with early endometrial cancer (EC) treated by combined hysteroscopic resection and progestin therapy. METHODS: Twenty-eight patients (stage IA, G1 and 2 endometrioid EC) wishing to preserve their fertility were enrolled into this prospective study. Hysteroscopic resection was used to resect the tumor, endometrium adjacent to the tumor and myometrium underlying the tumor. Adjuvant hormonal therapy consisted of oral megestrol acetate or levonorgestrel intrauterine device for 6 months or more. RESULTS: After 3 months from the progestin start date, 25 patients (89.3%) showed a complete regression (median time to complete regression, 3 months [range, 3-9 months]), two (7.1%) showed persistent disease, while one patient (3.6%) presented with progressive disease and underwent definitive surgery (stage IA, G3 endometrioid). At 6 months, one of the two patients with persistent disease underwent definitive surgery (stage IA, G1 endometrioid), while the other one was successfully re-treated. Two recurrences were observed (7.7%) both involving the endometrium and synchronous ovarian cancer. The median duration of complete response was 94.5 months (range, 8-175 months). More than half of the responders (57.7%) attempted to conceive with 93.3% and 86.6% pregnancy and live birth rates, respectively. CONCLUSION: The addition of a standardized three-step resectoscopy to progestin would seem to improve the efficacy of progestin alone. High pregnancy and live birth rates were observed in women attempting to conceive.
[Mh] Termos MeSH primário: Antineoplásicos Hormonais/administração & dosagem
Neoplasias do Endométrio/terapia
Preservação da Fertilidade/métodos
Histeroscopia
Acetato de Megestrol/administração & dosagem
Progestinas/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Quimioterapia Adjuvante
Terapia Combinada
Neoplasias do Endométrio/patologia
Feminino
Seres Humanos
Dispositivos Intrauterinos
Levanogestrel/administração & dosagem
Gravidez
Estudos Prospectivos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents, Hormonal); 0 (Progestins); 5W7SIA7YZW (Levonorgestrel); TJ2M0FR8ES (Megestrol Acetate)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160928
[St] Status:MEDLINE
[do] DOI:10.3802/jgo.2017.28.e2


  5 / 838 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27639080
[Au] Autor:Guk J; Son H; Chae DW; Park K
[Ad] Endereço:Department of Pharmacology, Yonsei University College of Medicine, Seoul, Korea.
[Ti] Título:Quantitative Assessment of Food Effect on the Pharmacokinetics of Nano-Crystallized Megestrol Acetate.
[So] Source:Basic Clin Pharmacol Toxicol;120(3):270-277, 2017 Mar.
[Is] ISSN:1742-7843
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Megestrol acetate, an appetite stimulant with low bioavailability, shows increased bioavailability when taken together with food. However, the pharmacokinetic characteristics of megestrol acetate and its relation with food are not well understood. This study aimed to investigate the food effect on the pharmacokinetics (PK) of the recently developed nano-crystallized megestrol acetate (NCMA), using a model-based approach. Data were obtained from an NCMA PK study consisting of a single dose in fasting (39 individuals) and fed conditions (40 individuals). Plasma concentrations were measured up to 120 hr after dosing. With the incorporation of body-weight via allometry, NONMEM 7.3 was used to develop a PK model, which was then used to simulate an optimal fasting dose yielding an area under concentration (AUC) and maximum concentration (C ) of NCMA close to those obtained with the fed dose. NCMA concentrations were best characterized by a two-compartment model with first-order absorption linked to a recycling compartment to account for the multiple concentration peaks observed. Food increased bioavailability 2.2 times and decreased the absorption rate constant 0.58 times. Recycling event times were estimated to be 3.56, 7.99 and 24.0 hr. The optimal fast dose was 2.0 times higher than the fed dose, and the resulting difference in drug exposure between the fasting and fed dose was 7.5%. This work suggests that the PK model developed can be applied to an optimal dosage regimen design for NCMA treatment.
[Mh] Termos MeSH primário: Estimulantes do Apetite/administração & dosagem
Estimulantes do Apetite/farmacocinética
Interações Alimento-Droga
Acetato de Megestrol/administração & dosagem
Acetato de Megestrol/farmacocinética
Modelos Biológicos
[Mh] Termos MeSH secundário: Administração Oral
Adulto
Estimulantes do Apetite/uso terapêutico
Disponibilidade Biológica
Caquexia/tratamento farmacológico
Estudos Cross-Over
Sistemas de Liberação de Medicamentos/métodos
Cálculos da Dosagem de Medicamento
Ingestão de Alimentos
Jejum
Voluntários Saudáveis
Seres Humanos
Masculino
Acetato de Megestrol/uso terapêutico
Nanopartículas
República da Coreia
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Appetite Stimulants); TJ2M0FR8ES (Megestrol Acetate)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170302
[Lr] Data última revisão:
170302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160918
[St] Status:MEDLINE
[do] DOI:10.1111/bcpt.12677


  6 / 838 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27343306
[Au] Autor:Gungor T; Cetinkaya N; Yalcin H; Zergeroglu S; Erkaya S
[Ad] Endereço:Zekai Tahir Burak Women's Health Education and Research Hospital, Department of Gynecologic Oncology, Ankara, Turkey.
[Ti] Título:Clinicopathologic characteristics and treatment features of women with the incidental diagnosis of endometrial adenocarcinoma during infertility follow-up in Ankara, Turkey.
[So] Source:Taiwan J Obstet Gynecol;55(3):309-13, 2016 Jun.
[Is] ISSN:1875-6263
[Cp] País de publicação:China (Republic : 1949- )
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The aim of this study was to investigate the clinical and laboratory features of patients with the incidental diagnosis of endometrial adenocarcinoma (EC) during infertility work-up, with special attention given to treatment approaches, recurrence rate, and fertility outcome. MATERIAL AND METHODS: The medical records of 577 patients who were diagnosed with EC and treated between 2007 and 2013 were included in the study. Out of 577 EC patients, 5.1% (n = 30) were ≤ 40 years of age. However, 10 patients had a history of infertility and had been diagnosed during evaluation for infertility. Patients' clinical and laboratory data were reviewed retrospectively. RESULTS: The mean age at diagnosis was 34.3 ± 4.5 years and the mean duration of infertility was 5.1 ± 4.7 years. Immediate staging surgery was performed on three patients. The others were treated with oral megestrol acetate and/or a levonorgestrel-containing intrauterine device (IUD) for 6 months. The mean duration of postoperative or postdiagnostic follow-up was 44.7 ± 25.9 months. The disease persistence and recurrence rates were 11.1% and 22.2%, respectively. Two patients achieved pregnancy naturally or by assisted reproductive technology (ART) trial. CONCLUSION: The investigation of patients during infertility work-up provides an opportunity to evaluate the endometrium and its malignancies in young women, when the disease is in its early stage and symptom free. The standard surgical treatment for early-stage EC is total hysterectomy with bilateral salpingo-oophorectomy. However, conservative management of early stage EC with progestational drugs, especially in young patients who wish to preserve their fertility, is acceptable with the possibility of future pregnancies.
[Mh] Termos MeSH primário: Adenocarcinoma/patologia
Adenocarcinoma/terapia
Neoplasias do Endométrio/patologia
Neoplasias do Endométrio/terapia
Infertilidade Feminina/complicações
Recidiva Local de Neoplasia/patologia
[Mh] Termos MeSH secundário: Adenocarcinoma/complicações
Adulto
Antineoplásicos Hormonais/uso terapêutico
Neoplasias do Endométrio/complicações
Feminino
Preservação da Fertilidade
Seres Humanos
Achados Incidentais
Dispositivos Intrauterinos Medicados
Levanogestrel/administração & dosagem
Acetato de Megestrol/uso terapêutico
Gradação de Tumores
Estadiamento de Neoplasias
Gravidez
Taxa de Gravidez
Estudos Retrospectivos
Turquia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents, Hormonal); 5W7SIA7YZW (Levonorgestrel); TJ2M0FR8ES (Megestrol Acetate)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170418
[Lr] Data última revisão:
170418
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160626
[St] Status:MEDLINE


  7 / 838 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27218795
[Au] Autor:Nanjappa S; Thai C; Shah S; Snyder M
[Ad] Endereço:Departments of Internal Medicine, Moffitt Cancer Center, Tampa, FL 33612, USA. Sowmya.Nanjappa@Moffitt.org.
[Ti] Título:Pharmacy Report: Megestrol Acetate-Induced Adrenal Insufficiency.
[So] Source:Cancer Control;23(2):167-9, 2016 Apr.
[Is] ISSN:1526-2359
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A man aged 65 years with metastatic renal cell carcinoma presented for evaluation after a recent fall. A thorough workup of the case was performed and secondary adrenal insufficiency induced by the administration of megestrol acetate was determined to be the cause. Adrenal insufficiency is a serious disorder that is a potential adverse event of megestrol acetate, a medication used to help patients with cancer cachexia increase their appetite and gain weight. This association is not well recognized in clinical practice, so this case highlights the importance of distinguishing possible endocrine complications induced by the long-term administration or sudden discontinuation of megestrol acetate.
[Mh] Termos MeSH primário: Insuficiência Adrenal/etiologia
Acetato de Megestrol/efeitos adversos
[Mh] Termos MeSH secundário: Idoso
Seres Humanos
Masculino
Acetato de Megestrol/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
TJ2M0FR8ES (Megestrol Acetate)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170310
[Lr] Data última revisão:
170310
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160525
[St] Status:MEDLINE


  8 / 838 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:27191767
[Au] Autor:Chae DW; Son H; Guk J; Park C; Park K
[Ti] Título:Pharmacokinetics of a nanocrystal-containing megestrol acetate formulation: a single-dose, randomized, open-label, 2-part, 2-period crossover study in healthy Korean subjects.
[So] Source:Int J Clin Pharmacol Ther;54(9):698-704, 2016 Sep.
[Is] ISSN:0946-1965
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:UNLABELLED: OBJECTIVE: The conventional suspension of megestrol acetate contains micronized megestrol acetate, which was recently discovered to have a disadvantage of decreasing bioavailability when taken in a fasting state. Since megestrol acetate is taken to increase appetite, this property becomes a discouraging factor. To improve upon this, an advanced formulation was developed using a nanocrystal drug-delivery system. This study was conducted to compare the safety and pharmacokinetic characteristics between the conventional formulation of megestrol acetate and a generic version of the advanced formulation containing nanocrystals. METHODS: This was a randomized, open-label, 2-period, 2-treatment, crossover, single-dose, 2-part study (part 1 fasting and part 2 fed), conducted in healthy males aged between 20 and 50 years with weight within ± 20% of ideal body weight having no congenital abnormalities or chronic diseases. Different subjects were used in part 1 and part 2, but subjects received a single dose of the reference and test drugs separated by a 14-day washout period. Blood sampling was performed up to 120 hours after dosing using a pre-specified sampling time scheme. Primary pharmacokinetic parameters were Cmax and AUClast of the test and reference formulations of megestrol acetate. Bioequivalence evaluation was based on the standard criterion of 80 - 125% for the 90% confidence interval of geometric mean ratios of test to reference drugs calculated for the pharmacokinetic parameters. To monitor adverse events, both subject interviews and physical examinations were done on a regular time basis. RESULTS: 80 subjects (n = 40 each part) were enrolled, and 79 completed the study. The 90% CIs of the geometric mean ratios of Cmax and AUClast were 4.4625 - 5.6018 and 1.3602 - 1.6418, respectively, for part 1, and 0.9793 - 1.1327 and 0.7721 - 0.8431, respectively, for part 2. No significant difference was discovered in the incidence of adverse events (AEs) when test and reference treated groups were compared. CONCLUSIONS: Our findings suggest that the test formulation of megestrol-acetate-containing nanocrystals is better absorbed and has higher bioavailability compared to the reference formulation in a fasting state. This should allow for a lower dose and better patient compliance.

ClinicalTrials.gov identifier: NCT02446353.
[Mh] Termos MeSH primário: Estimulantes do Apetite/farmacocinética
Medicamentos Genéricos/farmacocinética
Acetato de Megestrol/farmacocinética
Nanopartículas
[Mh] Termos MeSH secundário: Adulto
Estimulantes do Apetite/administração & dosagem
Área Sob a Curva
Grupo com Ancestrais do Continente Asiático
Disponibilidade Biológica
Estudos Cross-Over
Sistemas de Liberação de Medicamentos
Medicamentos Genéricos/administração & dosagem
Medicamentos Genéricos/efeitos adversos
Jejum
Seres Humanos
Masculino
Acetato de Megestrol/administração & dosagem
Acetato de Megestrol/efeitos adversos
Meia-Idade
Equivalência Terapêutica
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Appetite Stimulants); 0 (Drugs, Generic); TJ2M0FR8ES (Megestrol Acetate)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170203
[Lr] Data última revisão:
170203
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160519
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.5414/CP202574


  9 / 838 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27038209
[Au] Autor:Hua J; Han J; Wang X; Guo Y; Zhou B
[Ad] Endereço:State Key Laboratory of Freshwater Ecology and Biotechnology, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, China; University of Chinese Academy of Sciences, Beijing 100049, China.
[Ti] Título:The binary mixtures of megestrol acetate and 17α-ethynylestradiol adversely affect zebrafish reproduction.
[So] Source:Environ Pollut;213:776-784, 2016 Jun.
[Is] ISSN:1873-6424
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Synthetic progesterones and estrogens are broadly used bioactive pharmaceutical agents and have been detected in aquatic environments. In the present study, we investigated the combined reproductive effects of megestrol acetate (MTA) and 17α-ethinylestradiol (EE2) on zebrafish. Adult zebrafish were exposed to MTA (33, 100 or 333 ng/L), EE2 (10 ng/L) or a mixture of both (MTA + EE2: 33 + 10, 100 + 10 or 333 + 10 ng/L) for 21 days. Results demonstrated that egg production was significantly reduced by exposure to 10 ng/L EE2, but not MTA. However, a combined exposure to MTA and EE2 caused further reduction of fish fecundity compared to EE2 exposure alone, suggesting an additive effect on egg production when EE2 is supplemented with MTA. Plasma concentrations of 17ß-estradiol and testosterone in the females and 11-ketotestosterone in the males were significantly decreased in the groups exposed to EE2 or MTA alone compared with the solvent control, and the plasma concentrations of the three hormones were further reduced in the co-exposure groups relative to the MTA exposure group, but not the EE2 exposure group. These data indicate that the inhibitory effects on plasma concentrations in the co-exposures were predominantly caused by EE2. Furthermore, exposure to MTA and EE2 (alone or in combination) led to histological alterations in the ovaries (decreased vitellogenic/mature oocytes), but not in the testes. This study has important implications for environmental risk assessment of synthetic hormones that are concurrently present in aquatic systems.
[Mh] Termos MeSH primário: Etinilestradiol/toxicidade
Acetato de Megestrol/toxicidade
Reprodução/efeitos dos fármacos
Poluentes Químicos da Água/toxicidade
Peixe-Zebra/crescimento & desenvolvimento
[Mh] Termos MeSH secundário: Animais
Relação Dose-Resposta a Droga
Sinergismo Farmacológico
Feminino
Fertilidade/efeitos dos fármacos
Hormônios Esteroides Gonadais/sangue
Masculino
Ovário/efeitos dos fármacos
Ovário/patologia
Testículo/efeitos dos fármacos
Testículo/patologia
Testosterona/análogos & derivados
Testosterona/toxicidade
Peixe-Zebra/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Gonadal Steroid Hormones); 0 (Water Pollutants, Chemical); 3XMK78S47O (Testosterone); 423D2T571U (Ethinyl Estradiol); KF38W1A85U (11-ketotestosterone); TJ2M0FR8ES (Megestrol Acetate)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170802
[Lr] Data última revisão:
170802
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160403
[St] Status:MEDLINE


  10 / 838 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27016228
[Au] Autor:Myers AP; Filiaci VL; Zhang Y; Pearl M; Behbakht K; Makker V; Hanjani P; Zweizig S; Burke JJ; Downey G; Leslie KK; Van Hummelen P; Birrer MJ; Fleming GF
[Ad] Endereço:Dana Farber Cancer Institute, Boston, MA, United States. Electronic address: andrea.myers@novartis.com.
[Ti] Título:Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.
[So] Source:Gynecol Oncol;141(1):43-8, 2016 Apr.
[Is] ISSN:1095-6859
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Rapamycin analogs have reproducible but modest efficacy in endometrial cancer (EC). Identification of molecular biomarkers that predict benefit could guide clinical development. METHODS: Fixed primary tissue and whole blood were collected prospectively from patients enrolled on GOG 248. DNA was isolated from macro-dissected tumors and blood; next-generation sequence analysis was performed on a panel of cancer related genes. Associations between clinical outcomes [response rate (RR) 20%; progression-free survival (PFS) median 4.9months] and mutations (PTEN, PIK3CA, PIK3R1, KRAS, CTNNB1, AKT1, TSC1, TSC2, NF1, FBXW7) were explored. RESULTS: Sequencing data was obtained from tumors of 55 of the 73 enrolled pts. Mutation rates were consistent with published reports: mutations in PTEN (45%), PIK3CA (29%), PIK3R1 (24%), K-RAS (16%), CTNNB1 (18%) were common and mutations in AKT1 (4%), TSC1 (2%), TSC2 (2%), NF1 (9%) and FBXW7 (4%) were less common. Increased PFS (HR 0.16; 95% CI 0.01-0.78) and RR (response difference 0.83; 95% CI 0.03-0.99) were noted for AKT1 mutation. An increase in PFS (HR 0.46; 95% CI 0.20-0.97) but not RR (response difference 0.00, 95% CI -0.34-0.34) was identified for CTNNB1 mutation. Both patients with TSC mutations had an objective response. There were no statistically significant associations between mutations in PIK3CA, PTEN, PIK3R1, or KRAS and PFS or RR. CONCLUSIONS: Mutations in AKT1, TSC1 and TSC2 are rare, but may predict clinical benefit from temsirolimus. CTNNB1 mutations were associated with longer PFS on temsirolimus.
[Mh] Termos MeSH primário: Neoplasias do Endométrio/genética
Acetato de Megestrol/administração & dosagem
Mutação
Sirolimo/análogos & derivados
Tamoxifeno/administração & dosagem
[Mh] Termos MeSH secundário: Classe I de Fosfatidilinositol 3-Quinases
Neoplasias do Endométrio/tratamento farmacológico
Neoplasias do Endométrio/mortalidade
Feminino
Seres Humanos
PTEN Fosfo-Hidrolase/genética
Fosfatidilinositol 3-Quinases/genética
Estudos Prospectivos
Proteínas Proto-Oncogênicas c-akt/genética
Sirolimo/administração & dosagem
Sirolimo/uso terapêutico
Proteínas Supressoras de Tumor/genética
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Tumor Suppressor Proteins); 0 (tuberous sclerosis complex 1 protein); 094ZI81Y45 (Tamoxifen); 624KN6GM2T (temsirolimus); EC 2.7.1.- (Phosphatidylinositol 3-Kinases); EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases); EC 2.7.1.137 (PIK3CA protein, human); EC 2.7.11.1 (AKT1 protein, human); EC 2.7.11.1 (Proto-Oncogene Proteins c-akt); EC 3.1.3.67 (PTEN Phosphohydrolase); EC 3.1.3.67 (PTEN protein, human); TJ2M0FR8ES (Megestrol Acetate); W36ZG6FT64 (Sirolimus)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160327
[St] Status:MEDLINE



página 1 de 84 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde